Furthermore, PGAM1 suppression can reshape the immune landscape of HCC in a ferroptosis‐related manner and significantly improve the anti‐PD‐1 immunotherapeutic efficacy in HCC, which provides preclinical evidence for the application of this combination therapy. Here, PGAM1 is linked to hepatocellular carcinoma.